Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRUDHESA vs CAFERGOT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRUDHESA is a fixed-dose combination of sumatriptan (a serotonin 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug). Sumatriptan causes vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, while naproxen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation. Caffeine is a methylxanthine that enhances ergotamine absorption and may contribute to vasoconstriction.
Acute treatment of migraine with or without aura in adults
Acute treatment of migraine headaches with or without aura,Acute treatment of cluster headache episodes
10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.
1 to 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack or 10 tablets per week. Alternatively, 1 rectal suppository (ergotamine tartrate 2 mg and caffeine 100 mg) at onset, repeat once after 1 hour if needed, maximum 2 suppositories per attack or 5 per week.
Terminal elimination half-life is approximately 2.4 hours (range 1.7-3.6 hours) following intravenous administration. Clinical context: Due to rapid clearance, repeated dosing is recommended for acute migraine attacks.
2.5-3.9 hours (ergotamine); clinical context: t1/2 may be prolonged in hepatic impairment.
Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9 (major) and CYP1A2 (minor).
Primarily hepatic via CYP3A4; ergotamine is extensively metabolized, and caffeine is metabolized via CYP1A2.
Trudhesa (dihydroergotamine mesylate) is primarily eliminated via hepatic metabolism, with approximately 10% excreted unchanged in urine and 90% as metabolites in bile/feces.
Primarily hepatic metabolism and biliary excretion; less than 5% excreted unchanged in urine. Fecal elimination accounts for most of the administered dose.
Approximately 90-93% bound to plasma proteins, primarily to albumin.
98-99% bound to plasma proteins, primarily albumin.
Volume of distribution (Vd) is approximately 14 L/kg (range 10-20 L/kg), indicating extensive tissue distribution, including binding to serotonin receptors in the CNS.
1.1-2.0 L/kg; clinical meaning: extensive tissue distribution, particularly into liver and spleen.
Intranasal administration: Absolute bioavailability approximately 15-20% (range 10-30%), due to extensive first-pass hepatic metabolism.
Oral: <5% due to extensive first-pass metabolism; Sublingual: approximately 15-20%; Rectal: approximately 20-30%.
No dosage adjustment required for mild to moderate renal impairment; no data for severe impairment (e GFR <30 m L/min/1.73 m2).
Contraindicated in severe renal impairment. In moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): use with caution; dose reduction not specifically defined but monitor for adverse effects. Mild impairment (e GFR ≥60 m L/min/1.73 m²): no adjustment needed.
Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in moderate impairment (Child-Pugh class B) with no specific dose adjustment defined.
Contraindicated in Child-Pugh Class C. Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50% and monitor. No specific dose recommendations from manufacturer; clinical judgment advised.
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients due to risk of ergotism and lack of safety data. No established weight-based dosing.
No specific dose adjustment recommended, but consider potential increased sensitivity to adverse effects due to comorbidities or concomitant medications.
Use with caution due to increased risk of ergotism, renal/hepatic impairment, and drug interactions. Lower initial dose (e.g., 1 tablet) and careful monitoring. Avoid in patients over 65 with significant vascular disease.
Cardiovascular Risk: NSAIDs, including naproxen, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular risk factors or existing cardiovascular disease are at greater risk.
Serious and/or life-threatening peripheral ischemia has been associated with coadministration of ergotamine with potent CYP3A4 inhibitors (including protease inhibitors, macrolide antibiotics, and azole antifungals).
Cardiovascular and cerebrovascular effects; risk of myocardial infarction, stroke, and hypertension; gastrointestinal bleeding (NSAID-related); serotonin syndrome with concomitant serotonergic drugs; renal effects; anaphylactic reactions; exacerbation of asthma; sulfonamide allergy (cross-reactivity).
Risk of ergotism (ischemia, gangrene) with prolonged use or overdosage,May cause vasospastic reactions, including coronary artery vasospasm and myocardial infarction,Rebound headache (medication overuse headache) with frequent use,Caffeine withdrawal may exacerbate headaches,Avoid concurrent use with potent CYP3A4 inhibitors
History of ischemic heart disease, coronary artery disease, or cerebrovascular disease; peripheral vascular disease; uncontrolled hypertension; hemiplegic or basilar migraine; recent use (within 24 hours) of another 5-HT1 agonist or ergotamine; concurrent MAO-A inhibitor use; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; severe hepatic impairment; third trimester of pregnancy.
Peripheral vascular disease,Coronary artery disease,Hypertension (uncontrolled),Sepsis,Severe hepatic or renal impairment,Pregnancy (Category X),Breastfeeding,Concurrent use of potent CYP3A4 inhibitors
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4 and may increase ergotamine toxicity. No other significant food interactions reported.
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as Cafergot contains caffeine and may cause additive stimulation or toxicity. Limit caffeine to no more than 200 mg per day during treatment.
Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia and sulfonamide-related adverse effects.
FDA Category X. First trimester: ergotamine is a potent vasoconstrictor and uterine stimulant, associated with increased risk of spontaneous abortion, congenital anomalies (including micrognathia, microphthalmia, cleft palate, and limb defects). Second and third trimesters: continued risk of uteroplacental insufficiency, intrauterine growth restriction, preterm labor, and fetal distress due to vasoconstriction and increased uterine tone.
Topiramate is excreted into breast milk; M/P ratio 0.86. Infant exposure estimated at 10-20% of maternal weight-adjusted dose. Monitor for diarrhea, drowsiness, and poor feeding.
Contraindicated during breastfeeding. Ergotamine reduces prolactin secretion and may suppress lactation. It is excreted into breast milk; M/P ratio not established. Reported infant adverse effects include vomiting, diarrhea, and seizures. Risk of vasospasm and ergotism in the infant.
May require dose increase due to decreased plasma concentrations in pregnancy. Monitor topiramate levels and adjust dose to maintain therapeutic effect. Consider baseline and periodic monitoring.
Contraindicated in pregnancy; no dosing adjustments recommended. Use is not safe; alternative therapy should be sought.
TRUDHESA (dihydroergotamine mesylate) is an intranasal formulation for acute migraine. Administer one spray (0.5 mg) in each nostril, repeated after 15 minutes if needed (total 2 mg). Avoid in basilar or hemiplegic migraine due to vasospasm risk. Max dose: 3 mg/day, 4 mg/week. Contraindicated with CYP3A4 inhibitors (e.g., macrolides, azoles, protease inhibitors) due to ergotism risk. Monitor for signs of ischemia.
Cafergot is ergotamine-caffeine combination for acute migraine. Avoid in pregnancy, uncontrolled hypertension, CAD, and peripheral vascular disease. Maximum dose: 6 tablets per attack or 10 tablets per week. Use at first sign of migraine. Not for prophylaxis. Can cause ergotism with prolonged use. Monitor for signs of ischemia.
Use at the first sign of migraine; not for prevention.,Prime the pump 4 times before first use or if not used for 7+ days.,Do not exceed 2 sprays per nostril per attack or 8 sprays total per week.,Avoid within 24 hours of other triptans or ergotamines.,Seek medical help if symptoms of chest tightness, severe abdominal pain, or numbness occur.
Take at the first sign of migraine headache for best effect.,Do not take more than 6 tablets per attack or 10 tablets per week.,Avoid use if you are pregnant, breastfeeding, or have high blood pressure, heart disease, or circulation problems.,Seek emergency care if you experience severe stomach pain, chest pain, numbness, tingling, or muscle cramps.,Do not take with other ergotamine drugs or strong CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics).,Store at room temperature, away from heat and moisture.
No interactions on record
No interactions on record
Common clinical questions about TRUDHESA vs CAFERGOT, answered by our medical review team.
TRUDHESA is a Antimigraine (Ergot Alkaloid) that works by TRUDHESA is a fixed-dose combination of sumatriptan (a serotonin 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug). Sumatriptan causes vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, while naproxen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis.. CAFERGOT is a Antimigraine Agent (Ergot Alkaloid) that works by Ergotamine is a serotonin (5-HT1B/1D) receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation. Caffeine is a methylxanthine that enhances ergotamine absorption and may contribute to vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRUDHESA and CAFERGOT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRUDHESA is: 10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.. The standard adult dose of CAFERGOT is: 1 to 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack or 10 tablets per week. Alternatively, 1 rectal suppository (ergotamine tartrate 2 mg and caffeine 100 mg) at onset, repeat once after 1 hour if needed, maximum 2 suppositories per attack or 5 per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRUDHESA and CAFERGOT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRUDHESA is classified as Category C. Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia an. CAFERGOT is classified as Category C. FDA Category X. First trimester: ergotamine is a potent vasoconstrictor and uterine stimulant, associated with increased risk of spontaneous abortion, congenital anomalies (includi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.